Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Overview
Xeris Biopharma Holdings Inc (XERS) is a biopharmaceutical company that specializes in developing and commercializing innovative, ready-to-use biotherapeutics. The company is distinguished by its deep expertise in formulation science and biotherapeutic development, with a unique focus on addressing challenging conditions in the fields of endocrinology, neurology, and gastroenterology. By leveraging proprietary technologies such as XeriSol and XeriJect, Xeris aims to simplify treatment administration and improve patient outcomes through ultra-low volume injectable devices and patient-friendly formulations.
Core Technologies and Product Portfolio
Central to Xeris Biopharma’s mission is the use of breakthrough formulation science. The company’s proprietary technologies have been instrumental in creating products that stand out for their ease of use and direct applicability to clinical needs. XeriSol focuses on innovative formulation strategies while XeriJect has paved the way for ultra-low volume injectable devices that potentially mitigate the discomfort of traditional injection methods. This technological edge supports a portfolio that is uniquely positioned to serve patient populations requiring precise, efficient, and less invasive therapeutic solutions.
Commercial Products
Xeris has successfully brought several therapies to market that address critical conditions with new methods of administration. The product Gvoke offers ready-to-use liquid glucagon, designed for the rapid treatment of severe hypoglycemia, thereby ensuring swift and reliable relief during emergencies. Keveyis, another milestone, is recognized as the first FDA-approved therapy intended for primary periodic paralysis, marking a significant advancement in neuromuscular treatment options. Additionally, Recorlev provides an FDA-approved treatment for endogenous hypercortisolemia in adults with Cushing's Syndrome. Each of these commercial products not only meets specific therapeutic needs but also exemplifies the company’s commitment to refining drug delivery through advanced biotherapeutic formulations.
Innovative Pipeline and Formulation Science
Beyond its existing market offerings, Xeris Biopharma has a robust pipeline of development programs aimed at expanding its footprint in the biotherapeutic landscape. The company’s ongoing research utilizes its own formulation platforms to address unmet clinical needs. By continuously focusing on innovation in drug formulation and injectable delivery, Xeris demonstrates an unwavering commitment to pushing the boundaries of conventional treatment methodologies. Its efforts in refining ultra-low volume, ready-to-use biotherapeutics provide a strategic advantage, potentially alleviating the challenges associated with traditional injection therapies for hundreds of millions of patients.
Market Position and Competitive Landscape
Operating within the competitive arena of biopharmaceuticals, Xeris Biopharma holds a distinct niche due to its focus on patient-friendly, ready-to-use biotherapeutics. Its targeted approach in addressing conditions related to endocrinology, neurology, and gastroenterology distinguishes it from more traditional pharmaceutical companies. Positioned in a sector that demands constant innovation and a careful balance of safety and efficacy, Xeris has integrated rigorous formulation science with practical clinical applications, thus reinforcing its reputation as a company grounded in deep technical expertise and clinical insight.
Patient-Centric Approach and Value Proposition
The company’s innovative approach is underscored by its commitment to enhancing the treatment experience for patients. By developing therapies that are not only clinically effective but also easier to administer, Xeris focuses on lowering the barriers to treatment adherence. The incorporation of patient-friendly injectable devices, designed to ease the discomfort commonly associated with injections, speaks to a broader vision of improved quality of life. This patient-centric perspective is woven into every facet of the company’s operations, ensuring that every product is developed with the end-user’s comfort and convenience in mind.
Operational Excellence and Regulatory Rigor
Xeris Biopharma operates in an environment where compliance and clinical precision are paramount. The company’s products have undergone and continue to meet stringent regulatory standards, assuring stakeholders of both safety and efficacy. Through a disciplined regulatory strategy and a commitment to high-quality manufacturing practices, Xeris reinforces its position as a trusted entity in the formulation and delivery of biotherapeutics. This adherence to strict quality control further enhances the reliability of its products, establishing a strong foundation for long-term credibility in an increasingly competitive field.
Conclusion
In summary, Xeris Biopharma Holdings Inc presents a compelling case study in the integration of advanced formulation science with practical biotherapeutic applications. Its commercial products, such as Gvoke, Keveyis, and Recorlev, exemplify its ability to address diverse patient needs effectively. Supported by proprietary technologies like XeriSol and XeriJect, the company’s approach highlights a strategic blend of innovation, patient focus, and operational rigor. Through its commitment to developing ultra-low volume, ready-to-use therapies, Xeris continues to enhance treatment options within endocrinology, neurology, and gastroenterology, providing a clear reflection of expertise and a steadfast commitment to improved patient outcomes.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will report its third quarter 2021 financial results on November 10, 2021, before the U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company develops therapies in endocrinology, neurology, and gastroenterology, with products like Gvoke® and Keveyis®. Interested parties can pre-register for the call via the provided link, and a replay will be available until November 24, 2021.
Xeris Biopharma Holdings (Nasdaq: XERS) announced a collaboration with Merck to explore the licensing of its XeriJect™ technology for ultra-high concentration monoclonal antibodies. Although financial terms were not disclosed, this collaboration aims to improve the delivery of large molecules and is part of Xeris' ongoing partnerships with major pharmaceutical companies. Xeris highlighted the importance of its product portfolio, including commercialized therapies Gvoke® and Keveyis®, and a robust pipeline, indicating a solid financial position bolstered by a $50 million synergy from the Strongbridge acquisition.
Xeris Pharmaceuticals has successfully completed its acquisition of Strongbridge Biopharma, creating Xeris Biopharma Holdings. The deal values Strongbridge at approximately
Xeris Pharmaceuticals (NASDAQ: XERS) announced the grant of restricted stock units totaling 28,750 shares to 20 new employees as part of its Inducement Equity Plan, effective October 1, 2021. This plan incentivizes new hires not previously employed by Xeris, adhering to NASDAQ rules. The stock options will vest over four years, contingent on continued employment. Xeris is focused on innovative drug formulations, including its first commercial product, Gvoke, utilizing room-temperature stable formulations to enhance patient and healthcare provider experiences.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced that CEO Paul R. Edick will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 8:15 a.m. ET. The presentation can be accessed via the company's website. Xeris focuses on developing ready-to-use injectable drug formulations using its proprietary XeriSol™ and XeriJect™ technologies, which aim to simplify therapy administration and improve patient experiences. Xeris is headquartered in Chicago, IL.
Xeris Pharmaceuticals (XERS) has received overwhelming approval from its stockholders for the acquisition of Strongbridge Biopharma (SBBP). At a special meeting on September 14, 2021, approximately 97% of shares voted in favor, equating to about 59% of Xeris' total outstanding shares. The acquisition, set to close in early October 2021, will merge the businesses under Xeris Biopharma Holdings, Inc. This strategic move aims to strengthen Xeris' position in endocrinology and neurology, leveraging a differentiated technology platform to address unmet patient needs.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced that CEO Paul R. Edick will present an overview of the company during the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13, 2021, at 6:00 a.m. ET, accessible through the Investors section of the company’s website.
Xeris focuses on developing ready-to-use injectable drug formulations, including its first product, Gvoke®, leveraging innovative technologies for stability and ease of use.
Xeris Pharmaceuticals (NASDAQ: XERS) announced the successful enrollment and dosing of participants in a Phase 1 study of XP-8121, a novel subcutaneous formulation of levothyroxine for hypothyroidism. This study aims to evaluate pharmacokinetics, safety, and tolerability, with results expected in Q1 2022. Preliminary data suggest XP-8121 may overcome challenges associated with oral levothyroxine, such as dosage variability and medication adherence. The study involves 30 healthy participants and is conducted in partnership with Celerion.
Xeris Pharmaceuticals (Nasdaq: XERS) announced the FDA approval of its supplemental new drug application (sNDA) for the Gvoke® Kit, a ready-to-use injectable drug formulation for treating severe hypoglycemia in diabetes patients aged 2 and above. The Gvoke Kit will include a 1 mg/0.2 mL single-dose vial and syringe kit, enhancing patient convenience by eliminating the need for reconstitution. Manufacturing will commence immediately, with availability expected early in Q1 2022. The approval was backed by a pharmacokinetic study showing bioequivalence to the pre-filled syringe formulation.
Xeris Pharmaceuticals (Nasdaq: XERS) has announced the grant of three new patents concerning its formulation technologies. The U.S. Patent and Trademark Office issued U.S. Patent Nos. 10,987,399 and 11,020,403, covering storage-stable formulations of pramlintide and benzodiazepines, respectively. Additionally, the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 for pre-filled syringes utilizing Xeris’ XeriJect™ technology. These patents expand Xeris’ intellectual property portfolio, now totaling 121 patents worldwide, supporting innovation in therapies for diabetes and other conditions.
FAQ
What is the current stock price of Xeris Biopharma Holdings (XERS)?
What is the market cap of Xeris Biopharma Holdings (XERS)?
What is the primary focus of Xeris Biopharma Holdings?
What are the key commercial products offered by Xeris?
What proprietary technologies underpin Xeris's product development?
How does Xeris address the challenges associated with traditional injections?
In which therapeutic areas does Xeris operate?
What distinguishes Xeris's approach in the biopharmaceutical industry?
How does the company ensure the quality and safety of its products?
How is Xeris positioned within its competitive landscape?
